Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 1, 2010, Pages 254-258

  Min, Sherene ^a   Song, Ivy ^a   Borland, Julie ^a   Chen, Shuguang ^a   Lou, Yu ^a   Fujiwara, Tamio ^b   Piscitelli, Stephen C ^a  

^a GLAXOSMITHKLINE   (United States)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYTOCHROME P450 3A; GSK 1349572; MIDAZOLAM; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART VENTRICLE TACHYCARDIA; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; SORE THROAT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN;

ADULT; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HIV INTEGRASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; SLEEP STAGES; YOUNG ADULT;

EID: 73849124557     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00842-09     Document Type: Article

References (9)

1. Back, D., G. Gatti, C. Fletcher, R. Garaffo, R. Haubrich, R. Hoetelmans, M. Kurowski, A. Luber, C. Merry, and C. F. Perno. 2002. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 16(Suppl. 1):S5-S37.
2. DeJesus, E., D. Berger, M. Markowitz, C. Cohen, T. Hawkins, P. Ruane, R. Elion, C. Farthing, L. Zhong, A. K. Cheng, D. McColl, and B. P. Kearney for the 183-0101 Study Team. 2006. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naïve and treatment-experienced patients. J. Acquir. Immune Defic. Syndr. 43:1-5.
3. Markowitz, M., J. O. Morales-Ramirez, B. Y. Nguyen, C. M. Kovacs, R. T. Steigbigel, D. A. Cooper, R. Liporace, R. Schwartz, R. Isaacs, L. R. Gilde, L. Wenning, J. Zhao, and H. Teppler. 2006. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1 infected individuals. J. Acquir. Immune Defic. Syndr. 43:509-515.
4. Markowitz, M., B. Y. Nguyen, E. Gotuzzo, F. Mendo, W. Ratanasuwan, C. Kovacs, G. Prada, J. O. Morales-Ramirez, C. S. Crumpacker, R. D. Isaacs, L. R. Gilde, H. Wan, M. D. Miller, L. A. Wenning, and H. Teppler; Protocol 004 Part II Study Team. 2007. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune Defic. Syndr. 46:125-133.
5. National Institutes of Allergy and Infectious Diseases (NIAID), Division of Acquired Immunodeficiency Syndrome (DAIDS). December 2004. Table for grading the severity of adult and pediatric adverse events, version 1.0. http:// rcc.tech-res.com/Document/safetyandpharmacovigilance/DAIDS-AE -GradingTable-Clarification-August2009-Final.pdf.
6. Pommier, Y., A. A. Johnson, and C. Marchand. 2005. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 4:236-248.
7. Steigbigel, R. T., D. A. Cooper, P. N. Kumar, J. E. Eron, M. Schechter, M. Markowitz, M. R. Loutfy, J. L. Lennox, J. M. Gatell, J. K. Rockstroh, C. Katlama, P. Yeni, A. Lazzarin, B. Clotet, J. Zhao, J. Chen, D. M. Ryan, R. R. Rhodes, J. A. Killar, L. R. Gilde, K. M. Strohaier, A. R. Meibohm, M. D. Miller, D. J. Hazuda, M. L. Nessly, M. J. DiNubile, R. D. Isaacs, B. Y. Nguyen, and H. Teppler; BENCHMRK Study Teams. 2008. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 359:339-354.
8. Wenning, L. A., E. Hwang, B. Y. Nguyen, H. Teppler, R. Danovich, M. Iwamoto, J. Wagner, D. Panebianco, and J. Stone. 2008. Pharmacokinetic/ pharmacodynamic analyses for raltegravir in phase III studies in treatment-experienced HIV-infected patients following 48 weeks of treatment, abstr. H-4054. 48th Intersci. Conf. Antimicrob. Agents Chemother., Washington, DC. American Society for Microbiology, Washington, DC.
9. Zolopa, A. R., H. Lampiris, G. Blick, C. Walworth, L. Zhong, S. L. Chuck, B. P. Kearney, J. Enejosa, and A. K. Cheng. 2007. The HIV integrase inhibitor elvitegravir has potent and durable activity in treatment-experienced patients with active optimized background therapy, abstr. H-714. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL. American Society for Microbiology, Washington, DC.